Integrative Emergency Services

Belkins
Integrative Emergency Services (IES) is transforming the way healthcare is practiced across the continuum of care and furthering the emergency department’s role in value-based healthcare delivery. IES partners with physician groups to help create a culture of excellence through leadership, research, education, knowledge translation and data-driven decision-making. IES’s high-touch approach with physician groups provides both clinical and financial benefits, resulting in EDs that deliver high-value healthcare to patients and bring value to the bottom line.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

TARA BIOSYSTEMS PARTNERS WITH SCIPHER MEDICINE®

TARA Biosystems | November 03, 2021

news image

TARA Biosystemsa, biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies. Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. Thes...

Read More

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

news image

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

news image

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

news image

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More
news image

INDUSTRIAL IMPACT

TARA BIOSYSTEMS PARTNERS WITH SCIPHER MEDICINE®

TARA Biosystems | November 03, 2021

TARA Biosystemsa, biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies. Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. Thes...

Read More
news image

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More
news image

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More
news image

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More